Journal
MOLECULAR CANCER THERAPEUTICS
Volume 21, Issue 5, Pages 762-774Publisher
AMER ASSOC CANCER RESEARCH
DOI: 10.1158/1535-7163.MCT-21-0142
Keywords
-
Categories
Funding
- NIH [F30CA243253, T32 CA071341, F32CA221005, F32CA200313, T32CA009156, P01CA203657, R01CA42978, R35CA232113]
- Royster Society
- American Cancer Society [PF-18-061]
- Slomo and Cindy Silvian Foundation
Ask authors/readers for more resources
HPV-negative head and neck squamous cell carcinoma (HNSCC) is a common cancer with limited treatment options. This study investigated the potential of the farnesyltransferase inhibitor tipifarnib as a therapeutic strategy for HRAS-mutant HNSCC. The results suggest that tipifarnib shows promise in targeting HRAS and its effector signaling, and combination treatments may enhance its effectiveness.
Human papilloma virus (HPV)-negative head and neck squamous cell carcinoma (HNSCC) is a common cancer worldwide with an unmet need for more effective, less toxic treatments. Currently, both the disease and the treatment of HNSCC cause significant mortality and morbidity. Targeted therapies hold new promise for patients with HPV-negative status whose tumors harbor oncogenic HRAS mutations. Recent promising clinical results have renewed interest in the development of farnesyltransferase inhibitors (FTIs) as a therapeutic strategy for HRAS-mutant cancers. With the advent of clinical evaluation of the FTI tipifarnib for the treatment of HRAS-mutant HNSCC, we investigated the activity of tipifarnib and inhibitors of HRAS effector signaling in HRAS-mutant HNSCC cell lines. First, we validated that HRAS is a cancer driver in HRAS-mutant HNSCC lines. Second, we showed that treatment with the FTI tipifarnib largely phenocopied HRAS silencing, supporting HRAS as a key target of FTI antitumor activity. Third, we performed reverse-phase protein array analyses to profile FTI treatment-induced changes in global signaling, and conducted CRISPR/Cas9 genetic loss-of-function screens to identify previously unreported genes and pathways that modulate sensitivity to tipifarnib. Fourth, we determined that concurrent inhibition of HRAS effector signaling (ERK, PI3K, mTORC1) increased sensitivity to tipifarnib treatment, in part by overcoming tipifarnib-induced compensatory signaling. We also determined that ERK inhibition could block tipifarnib-induced epithelial-to-mesenchymal transition, providing a potential basis for the effectiveness of this combination. Our results support future investigations of these and other combination treatments for HRAS mutant HNSCC.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available